BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership lifted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXGet Rating) by 2.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,917,209 shares of the biotechnology company’s stock after buying an additional 75,804 shares during the quarter. Artisan Partners Limited Partnership owned approximately 1.57% of BioCryst Pharmaceuticals worth $30,864,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Semmax Financial Advisors Inc. raised its stake in BioCryst Pharmaceuticals by 389.6% in the 1st quarter. Semmax Financial Advisors Inc. now owns 1,699 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,352 shares during the last quarter. Fairfield Bush & CO. acquired a new position in BioCryst Pharmaceuticals in the 1st quarter valued at about $34,000. Lazard Asset Management LLC acquired a new position in BioCryst Pharmaceuticals in the 1st quarter valued at about $57,000. Xponance Inc. acquired a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at about $107,000. Finally, Point72 Hong Kong Ltd acquired a new position in BioCryst Pharmaceuticals in the 1st quarter valued at about $118,000. Institutional investors and hedge funds own 80.68% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on BCRX. Evercore ISI raised shares of BioCryst Pharmaceuticals from an “in-line” rating to an “outperform” rating and boosted their target price for the company from $14.00 to $16.00 in a research note on Wednesday, November 2nd. StockNews.com began coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Royal Bank of Canada dropped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 2nd. Oppenheimer downgraded shares of BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, August 5th. Finally, Barclays upped their price objective on shares of BioCryst Pharmaceuticals from $12.00 to $14.00 and gave the company an “equal weight” rating in a research note on Friday, August 5th. Six research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $17.00.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, insider Yarlagadda S. Babu sold 31,515 shares of the company’s stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $13.88, for a total value of $437,428.20. Following the completion of the transaction, the insider now owns 298,541 shares in the company, valued at approximately $4,143,749.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.00% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 2.4 %

Shares of NASDAQ:BCRX opened at $12.39 on Thursday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $7.61 and a 1 year high of $19.99. The stock has a 50-day simple moving average of $13.09 and a 200-day simple moving average of $12.03.

BioCryst Pharmaceuticals Company Profile

(Get Rating)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Further Reading

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.